Abstract
Purpose The SARS-CoV-2 coronavirus is a respiratory virus whose primary route of transmission is airborne. However, it has been shown that the virus can replicate in gastrointestinal cells, can be excreted in feces, and can reach sewage systems. Although viral RNA has been found in patient feces and sewage, little is known about the potential fecal-oral transmission of the coronavirus. Determining the presence of infective viral particles in feces and sewage is necessary to take adequate control measures and to discover new routes of coronavirus transmission.
Methods Feces and urine of COVID-19 patients, and wastewater samples at the time of high prevalence in the region under study (Valencia, Spain), have been analyzed both by molecular methods and cell culture.
Results Presence of SARS-CoV-2 in feces of COVID-19 patients has been detected, even in patients without gastrointestinal symptoms, suggesting that viral shedding though stool is common. In addition, we have developed a sample concentration methodology that allows us to maintain the infectivity of the viral particles present in the samples. Finally, inoculation of cell cultures with fecal and sewage concentrated samples do not evidence the presence of infective viral particles.
Conclusion There is no evidence of the presence of infectious SARS-CoV-2 in feces and sewage, suggesting that fecal-oral transmission is not a primary route. However, larger-scale efforts are needed to elucidate whether the fecal-oral transmission should be considered, especially with the emergence of new viral variants.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by FONDO-COVID19 COV20/00210 funded by Instituto de Salud Carlos III to P.D-C. P.D-C. was supported by a Ramon y Cajal contract from the Spanish Ministry of Science and Innovation, Call 2021.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has been approved by the ethics committee of the Instituto de Investigacion Sanitaria La Fe (Valencia, Spain) to use patient samples, including urine and feces.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available on request from the corresponding author.
